Redeye updates its estimates and valuation following Serstech's Q3 2024 report. Sales, as expected, were significantly below forecasted figures, although solid cost control was a mitigating factor. Forecasts are revised downwards for 2024e based on management commentary, which results in a lowered fair value range. Nevertheless, Redeye's Base Case still indicates a 60% upside to the current share price, and we expect strong order intake during year-end and early 2025e to close the gap.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/